trpS Antibody

• How does TRPS1 expression compare between different breast cancer subtypes, particularly in triple-negative breast cancer?

TRPS1 shows differential expression across breast cancer subtypes:

TCGA data indicates that TRPS1 is a specific gene for breast carcinoma across multiple solid tumor types, including all four major subtypes: ER/PR-positive luminal A and B types, HER2-positive type, and basal-type/TNBC .

In invasive breast carcinoma of no special type, low TRPS1 expression correlates with:

• High grade (P = 0.0547)

• High pT stage (P < 0.0001)

• Nodal metastasis (P = 0.0571)

• Loss of estrogen receptor and progesterone receptor expression (P < 0.0001 each)

• Triple-negative status (P < 0.0001)

• What are the comparative advantages of using TRPS1 versus GATA3 as diagnostic markers for breast cancer?

TRPS1 offers several distinct advantages over the commonly used GATA3 marker:

GATA3 has traditionally been used to determine breast origin for ER-positive and low-grade breast cancer but demonstrates poor sensitivity (<20%) in metaplastic breast carcinomas such as TNBC . The virtual absence of TRPS1 positivity in urothelial neoplasms (only 1.8% of 1083 cases) makes it particularly useful for distinguishing GATA3-positive urothelial carcinoma from breast cancer .

Co-positivity for both TRPS1 and GATA3 is observed in:

• 47.4% to 100% of breast cancers

• Up to 30% of salivary gland tumors

• Only 29 (0.3%) of 9835 tumors from 134 other cancer entities

• What methods should be employed to optimize TRPS1 antibody-based detection systems?

For optimal TRPS1 antibody-based detection, researchers should consider:

Sample preparation:

• For Western blot: Use RIPA or similar buffer with protease inhibitors; load 15-50 μg protein

• For IHC: Formalin-fixed paraffin-embedded (FFPE) tissue with antigen retrieval using TE buffer pH 9.0 or citrate buffer pH 6.0

Antibody selection considerations:

• Different clones yield varying staining patterns and intensities

• MSVA-512R and EPR16171 antibody clones show comparable nuclear staining in target tissues

• EPR16171 shows additional cytoplasmic staining in basal cells of non-keratinizing squamous epithelia

Dilution optimization by application:

• Western Blot: 1:1000-1:10000

• IHC: 1:200-1:800

• Flow Cytometry: 0.25 μg per 10^6 cells

• Immunofluorescence: 1:50-1:500

Storage conditions:

• Store antibody at -20°C (most antibodies) or -80°C (conjugation-ready formats)

• Stable for one year after shipment

• Aliquoting may be unnecessary for -20°C storage

• For concentrated antibodies, centrifuge prior to use to ensure recovery of all product

• How can TRPS1 antibodies be used for investigating protein-protein interactions in cancer biology?

TRPS1 is involved in complex protein-protein interactions that influence cancer biology. Research methodologies include:

Immunoprecipitation approaches:

• Use 0.5-4.0 μg antibody for 1.0-3.0 mg of total protein lysate

• Validated in mouse lung tissue and HeLa cells

• Recommended protocol: Incubate antibody with lysate overnight at 4°C, followed by addition of protein A/G beads

Investigating TRPS1 interactions with chromatin modifiers:
Studies have identified interactions between TRPS1 and chromatin-modifying complexes:

• TRPS1 recruits CHD4/NuRD(MTA2) complex

• TRPS1 represses gene expression through these interactions

• TRPS1 suppresses cell migration and invasion by repressing TP63 expression

TRPS1 and SOX2 transcription:
Research has shown that CHD4 mediates SOX2 transcription through TRPS1 in luminal breast cancer . This pathway can be studied using:

• Co-immunoprecipitation with TRPS1 antibodies

• ChIP sequencing to identify genomic binding sites

• Expression analysis after TRPS1 knockdown/overexpression

• What are the methodological considerations for using TRPS1 antibodies in multiplexed detection systems?

When incorporating TRPS1 antibodies into multiplexed detection systems:

For multiplex immunohistochemistry:

• TRPS1 provides nuclear staining pattern, allowing for clear distinction from cytoplasmic/membrane markers

• Compatible with other nuclear markers when using different visualization systems

• Consider cross-reactivity when selecting compatible primary antibodies from different host species

For flow cytometry multiplex panels:

• TRPS1 requires permeabilization protocols for intracellular/nuclear staining

• Use 0.25 μg per 10^6 cells in a 100 μl suspension

• Has been validated in MCF-7 cells

For multiplex imaging applications:

• Conjugation-ready formats (BSA and azide-free) available at 1 mg/mL concentration

• Compatible with various conjugation chemistries for fluorescent or mass cytometry applications

• For optimal results, titrate antibody dilution for each specific application

For matched antibody pair applications:
Available matched antibody pairs (e.g., MP50280-1: 68562-2-PBS capture and 68562-3-PBS detection) have been validated for:

• Cytometric bead arrays

• Multiplex assays

• ELISA applications

• How can researchers evaluate and validate the specificity of TRPS1 antibodies in their experimental systems?

To ensure TRPS1 antibody specificity:

Positive control selection:

• Breast tissue (normal and carcinoma)

• Ductal breast carcinoma

• Triple-negative carcinoma

• Fallopian tubes

• MCF-7 cells (breast cancer cell line)

Negative control considerations:

• Urothelial carcinoma (typically negative)

• Lung adenocarcinoma

• Melanoma

• Include isotype control antibodies in parallel experiments

Western blot validation:

• Expected molecular weight: 142-143 kDa (calculated)

• Observed molecular weight: 150-165 kDa

• Single specific band should be detected

Knockdown/knockout validation:

• siRNA or CRISPR/Cas9-mediated TRPS1 knockdown/knockout

• Compare staining pattern and intensity before and after TRPS1 depletion

• RNA-level confirmation using qRT-PCR to correlate with protein expression

• What technical challenges might researchers encounter when using TRPS1 antibodies and how can these be addressed?

Common technical challenges with TRPS1 antibodies include:

Challenge: Variable background staining

• Solution: Optimize blocking conditions (5% BSA or 5% normal serum from secondary antibody host species)

• Solution: Include longer washing steps (3-5x for 5 minutes each)

• Solution: Consider using more diluted antibody concentration with longer incubation time

Challenge: Inconsistent nuclear staining

• Solution: Ensure proper fixation and permeabilization

• Solution: Optimize antigen retrieval (TE buffer pH 9.0 recommended, or citrate buffer pH 6.0)

• Solution: Extend primary antibody incubation time (overnight at 4°C)

Challenge: Cross-reactivity in specific tissues

• Solution: Compare results from multiple TRPS1 antibody clones

• Solution: Include appropriate tissue-specific negative controls

• Solution: Consider additional markers for confirmatory analysis

Challenge: Differentiation between stromal and epithelial staining

• Solution: Use dual staining with epithelial markers

• Solution: Nuclear TRPS1 staining is regularly observed in stromal cells of various tissues, especially during tissue reparation (likely fibroblasts)

• How can TRPS1 antibodies be utilized in research on tumor heterogeneity and cancer evolution?

TRPS1 antibodies can contribute to cancer heterogeneity research through:

Single-cell analysis:

• Flow cytometry combining TRPS1 with other markers can identify distinct cellular subpopulations

• TRPS1 expression varies across breast cancer subtypes, providing a window into tumor evolution

• Low TRPS1 expression correlates with higher grade and more aggressive phenotypes in breast cancer

Spatial profiling approaches:

• Multiplex immunofluorescence with TRPS1 antibodies can map expression patterns within the tumor microenvironment

• Digital spatial profiling techniques can quantify TRPS1 expression at the single-cell level in tissue context

• Regional variation in TRPS1 expression may indicate different tumor evolutionary trajectories

Monitoring therapeutic response:

• Changes in TRPS1 expression patterns before and after treatment may indicate selection of resistant clones

• Research methodology: Paired pre- and post-treatment biopsies with TRPS1 IHC quantification

• Consider correlation with patient outcomes and response to specific therapeutic approaches

Research considerations:

• Combine TRPS1 analysis with genomic profiling (e.g., single-cell sequencing)

• Account for stromal TRPS1 staining when assessing tumor heterogeneity

• Correlate TRPS1 expression with markers of stem cell-like properties and differentiation status

Technical Applications and Protocols

• What are the optimal protocols for using TRPS1 antibodies in various research applications?

Western Blot Protocol:

• Prepare cell/tissue lysates using RIPA buffer with protease inhibitors

• Load 15-50 μg protein per lane

• Separate proteins using SDS-PAGE (8-10% gel recommended for 143 kDa protein)

• Transfer to PVDF membrane (overnight transfer may improve efficiency for large proteins)

• Block with 5% non-fat milk or BSA in TBST for 1 hour at room temperature

• Incubate with TRPS1 antibody (1:1000-1:10000 dilution) overnight at 4°C

• Wash 3x with TBST, 5 minutes each

• Incubate with HRP-conjugated secondary antibody (typically 1:5000-1:10000) for 1 hour

• Wash 3x with TBST, 5 minutes each

• Develop using ECL substrate with exposure time of 30 seconds to 3 minutes

Immunohistochemistry Protocol:

• Deparaffinize and rehydrate FFPE tissue sections

• Perform antigen retrieval using TE buffer pH 9.0 (recommended) or citrate buffer pH 6.0

• Block endogenous peroxidase activity with 3% H₂O₂

• Block non-specific binding with 5% normal serum

• Incubate with TRPS1 antibody (1:200-1:800 dilution) overnight at 4°C

• Wash 3x with PBS, 5 minutes each

• Apply appropriate secondary antibody/detection system

• Develop with DAB or other chromogen

• Counterstain with hematoxylin

• Dehydrate, clear, and mount

Flow Cytometry Protocol:

• Harvest cells and wash in PBS

• Fix cells with 4% paraformaldehyde for 15 minutes

• Permeabilize with 0.1% Triton X-100 for 10 minutes

• Block with 5% normal serum for 30 minutes

• Incubate with TRPS1 antibody (0.25 μg per 10^6 cells) for 30-60 minutes

• Wash 2x with PBS + 0.1% BSA

• Incubate with fluorochrome-conjugated secondary antibody

• Wash 2x with PBS + 0.1% BSA

• Resuspend cells and analyze by flow cytometry

• What controls should be included when using TRPS1 antibodies in experimental design?

A robust experimental design with TRPS1 antibodies should include:

Positive controls:

• Breast cancer cell lines (MCF-7, MDA-MB-453)

• Breast carcinoma tissue

• Ductal breast carcinoma in situ tissue

• Fallopian tubes (for non-breast tissue positive control)

Negative controls:

• Isotype control antibody at the same concentration as TRPS1 antibody

• Tissues known to lack TRPS1 expression (e.g., melanoma, urothelial carcinoma)

• Secondary antibody-only controls to assess background

Technical controls:

• Dilution series to establish optimal antibody concentration

• Different antigen retrieval methods if IHC signal is weak

• Positive internal controls within tissue samples (e.g., normal breast epithelial cells)

Validation controls:

• TRPS1 knockdown/knockout samples

• Multiple TRPS1 antibody clones targeting different epitopes

• Correlation with TRPS1 mRNA expression data

• How can TRPS1 antibodies contribute to research on cancer therapeutics and biomarker development?

TRPS1 antibodies offer valuable tools for cancer therapeutics research:

As diagnostic biomarkers:

• TRPS1 shows high sensitivity for breast cancer detection (expressed in >90% of cases)

• Particularly valuable for triple-negative breast cancer, where traditional markers like ER/PR/HER2 are negative

• Combinatorial approach with GATA3 provides enhanced diagnostic accuracy

For treatment response monitoring:

• Changes in TRPS1 expression levels before and after therapy may indicate treatment efficacy

• Low TRPS1 expression correlates with more aggressive disease features

• Methodology: Serial biopsies with standardized IHC and quantification

In therapeutic target identification:

• TRPS1 interactions with chromatin modifiers like CHD4/NuRD(MTA2) suggest potential druggable pathways

• TRPS1 represses gene expression through these interactions

• TRPS1 suppresses cell migration and invasion by repressing TP63 expression

• CHD4 mediates SOX2 transcription through TRPS1 in luminal breast cancer

For antibody-drug conjugate development:

• TRPS1's high expression in breast cancer makes it a candidate target for ADC development

• Nuclear localization presents challenges but internalization mechanisms might be exploited

• Research approach: Evaluate antibody internalization in cell line models using fluorescently-labeled antibodies

• What recent advances in TRPS1 antibody development are relevant to cutting-edge cancer research?

Recent advances include:

New antibody clones with enhanced specificity:

• Multiple validated clones now available (MSVA-512R, EP392, EPR16171, 1D6, 8D11, RM518, OTI3B2, 1B1G2, 8008R)

• These clones vary in their staining performance, offering researchers options for specific applications

• Some clones show additional cytoplasmic staining in basal cells of non-keratinizing squamous epithelia

Conjugation-ready formats:

• BSA and azide-free preparations for customized conjugation chemistry

• Enables applications in multiplex assays, mass cytometry, and multiplex imaging

• Available as matched antibody pairs for cytometric bead arrays

Expanded validation across diverse tissues:

• Comprehensive studies across 19,201 samples from 152 tumor types

• Detailed characterization of expression in soft tissue tumors, salivary gland tumors, squamous cell carcinomas, and gynecological cancers

• Better understanding of non-breast tissue expression informs more precise diagnostic applications

Integration with computational approaches:

• Similar to developments with other antibodies, machine learning models can now help predict thermal stability of antibodies

• These approaches could potentially optimize TRPS1 antibody design and performance

• Methodology includes deep learning models trained on antibody sequences to predict biophysical properties

Research Examples and Case Studies

• How have researchers successfully utilized TRPS1 antibodies in advancing breast cancer research?

Case Study 1: TRPS1 as a biomarker for triple-negative breast cancer
Researchers have demonstrated that TRPS1 provides superior sensitivity for TNBC compared to traditional markers. While GATA3 shows only 21% positivity in metaplastic TNBC, TRPS1 maintains 86% positivity, significantly enhancing diagnostic capabilities. This has led to adoption of TRPS1 antibodies in difficult diagnostic cases where traditional markers fail .

Case Study 2: TRPS1's role in transcriptional regulation
Studies using TRPS1 antibodies have revealed that TRPS1 recruits CHD4/NuRD(MTA2) complex to repress gene expression. The research demonstrated that TRPS1 suppresses cell migration and invasion by repressing TP63 expression. This work provided important insights into breast cancer biology and potential therapeutic targets .

Case Study 3: CHD4-mediated SOX2 transcription through TRPS1
Researchers identified that CHD4 mediates SOX2 transcription through TRPS1 in luminal breast cancer, revealing a novel mechanism in breast cancer development. This research utilized TRPS1 antibodies for various assays including western blot and immunoprecipitation .

Case Study 4: Comprehensive tissue profiling
A large-scale study analyzed TRPS1 expression across 19,201 samples from 152 tumor types, establishing the specificity profile of TRPS1 as a diagnostic marker. This research found TRPS1 staining in 86 tumor categories but demonstrated its particular enrichment in breast cancer .

• What research questions about TRPS1 remain unanswered and how might antibody-based approaches help address them?

Unanswered Question 1: TRPS1's role in breast cancer initiation and progression

• Research approach: Time-course studies using TRPS1 antibodies in breast cancer models

• Methodology: Analyze TRPS1 expression patterns across different stages of cancer development

• Combine with lineage tracing approaches and additional markers of cancer evolution

Unanswered Question 2: Mechanisms of TRPS1 regulation in response to therapy

• Research approach: Monitor TRPS1 expression before and after various therapeutic interventions

• Methodology: Paired patient samples with standardized IHC protocols

• Correlate changes with treatment response and patient outcomes

Unanswered Question 3: TRPS1's interaction network beyond currently identified partners

• Research approach: Immunoprecipitation with TRPS1 antibodies followed by mass spectrometry

• Methodology: Compare interaction networks across different breast cancer subtypes

• Validate interactions with co-immunoprecipitation and proximity ligation assays

Unanswered Question 4: TRPS1's potential as a therapeutic target

• Research approach: Develop antibodies that could modulate TRPS1 function

• Methodology: Screen antibodies for their ability to alter TRPS1-dependent gene expression

• Evaluate phenotypic consequences in cell line and animal models

Unanswered Question 5: TRPS1's role in resistance mechanisms

• Research approach: Compare TRPS1 expression in therapy-resistant versus sensitive tumors

• Methodology: Develop models with acquired resistance and analyze TRPS1 pathways

• Use TRPS1 antibodies to identify changes in protein localization or post-translational modifications